Detection of recurrent brain tumors in children: No significant difference in sensitivity between unenhanced and contrast-enhanced MRI

Abstract

Background

Magnetic resonance imaging (MRI) with a gadolinium injection is currently used in the follow-up of children in remission of cerebral tumors (CTs). Intracerebral gadolinium deposition has been recently reported with unknown risks. The aim of this study was to evaluate the sensitivity of unenhanced brain MRI (U-MRI) in detection of tumor recurrence.

Methods and materials

A set of 58 U-MRIs of children in remission was retrospectively evaluated by three seniors (a neuroradiologist, a pediatric and a general radiologist) and one junior to look for any recurrence. Clinical, tumoral and imaging data were collected. The final diagnosis was anatomopathological when available, or the clinicoradiological evolution. Sensitivity, specificity, predictive values and interobserver agreement were calculated. A Fisher test and Fleiss kappa coefficient were performed.

Results

For the seniors, the U-MRI had a sensitivity of 81% (95% confidence interval (CI): 0.56–0.90), and a negative predictive value (NPV) of 82% (95% CI: 0.63–0.94). The U-MRI sensitivity, regardless of the observer, was not significantly different from the contrast-enhanced MRI sensitivity (86%) according to a Fisher test (p > 0.05). No significant difference in sensitivity within the subgroups was found. The interobserver agreement of seniors was good (κ = 0.68).

Conclusion

U-MRI brain was suboptimal for 80% of patients. Three-dimensional millimetric, fluid-attenuated inversion recovery, and diffusion would constitute helpful sequences in follow-up. Further specific studies depending on each tumor type are still required to determine whether a potential abstention of gadolinium intravenous injection should be discussed for children.

Keywords

Brain MRI cerebral tumor child gadolinium neoplasm recurrence pediatric radiology

Get full access to this article

View all access options for this article.

References

Young

Ries

Silverberg

et al.

Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986; 58: 598–602.

Bauchet

Rigau

Mathieu-Daudé

et al.

Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol 2009; 92: 87–98.

Ostrom

Gittleman

Liao

et al.

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncol 2014; 16(Suppl 4): iv1–iv63.

Koob

Girard

. Tumeurs cérébrales: Particularités chez l’enfant. J Radiol Diagn Interv 2014; 95: 953–972.

Unger

Needleman

Cullis

et al.

Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. Invest Radiol 1988; 23: 928–932.

Tedeschi

Caranci

Giordano

et al.

Gadolinium retention in the body: What we know and what we can do. Radiol Med 2017; 122: 589–600.

Malikova

Holesta

. Gadolinium contrast agents —Are they really safe? J Vasc Access 2017; 18(Suppl 2): 1–7.

Kanda

Fukusato

Matsuda

et al.

Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276: 228–232.

Kanda

Oba

Toyoda

et al.

Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016; 34: 3–9.

10.

Olchowy

Cebulski

Łasecki

et al.

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity—A systematic review. PLoS One 2017; 12: e0171704.

11.

Stojanov

Aracki-Trenkic

Benedeto-Stojanov

. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents—current status. Neuroradiology 2016; 58: 433–441.

12.

Kinner

Schubert

Bruce

et al.

Deep brain nuclei T1 shortening after gadobenate dimeglumine in children: Influence of radiation and chemotherapy. Am J Neuroradiol 2018; 39: 24–30.

13.

Rossi Espagnet

Bernardi

Pasquini

et al.

Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol 2017; 47: 1345–1352.

14.

Bhargava

Hahn

Hirsch

et al.

Contrast-enhanced magnetic resonance imaging in pediatric patients: Review and recommendations for current practice. Magn Reson Insights 2013; 6: 95–111.

15.

Warren

Poussaint

Vezina

et al.

Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group: Response assessment in pediatric brain tumors. Pediatr Blood Cancer 2013; 60: 1397–1401.

16.

Warren

Vezina

Poussaint

et al.

Response assessment in medulloblastoma and leptomeningeal seeding tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncol 2018; 20: 13–23.

17.

Dünger

Krause

Gräfe

et al.

Do we need gadolinium-based contrast medium for brain magnetic resonance imaging in children?

Pediatr Radiol 2018; 48: 858–864.

18.

Salerno

Granata

Trapenese

et al.

Is MRI imaging in pediatric age totally safe? A critical reprisal. Radiol Med 2018; 123: 695–702.

19.

Udaka

Yeh-Nayre

Amene

et al.

Recurrent pediatric central nervous system low-grade gliomas: The role of surveillance neuroimaging in asymptomatic children. J Neurosurg Pediatr 2013; 11: 119–126.

20.

De Oliveira

Gonzalez-Gomez

Panigrahy

et al.

False-positive magnetic resonance imaging findings in follow-up of pediatric patients with tumors of the central nervous system. SAGE Open Med Case Rep 2016; 4: 2050313X16666232.

21.

Sabel

Fleischhack

Tippelt

et al.

Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study. J Neurooncol 2016; 129: 515–524.

22.

Perreault

Lober

Carret

et al.

Relapse patterns in pediatric embryonal central nervous system tumors. J Neurooncol 2013; 115: 209–215.

23.

Rochetams

Marechal

Cottier

et al.

T1-weighted dynamic contrast-enhanced brain magnetic resonance imaging: A preliminary study with low infusion rate in pediatric patients. Neuroradiol J 2017; 30: 429–436.

24.

Rollins

Mendelsohn

Mulne

et al.

Recurrent medulloblastoma: Frequency of tumor enhancement on Gd-DTPA MR imaging. AJNR Am J Neuroradiol 1990; 11: 583–587.

25.

Morana

Alves

Tortora

et al.

Added value of diffusion weighted imaging in pediatric central nervous system embryonal tumors surveillance. Oncotarget 2017; 8: 60401–60413.

26.

Guerit

Liebner

. Blood-brain barrier breakdown determines differential therapeutic outcome in genetically diverse forms of medulloblastoma. Cancer Cell 2016; 29: 427–429.

27.

Perreault

Ramaswamy

Achrol

et al.

MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014; 35: 1263–1269.

28.

Bühring

Strayle-Batra

Freudenstein

et al.

MRI features of primary, secondary and metastatic medulloblastoma. Eur Radiol 2002; 12: 1342–1348.

29.

Fouladi

Gajjar

Boyett

et al.

Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 1999; 17: 3234–3237.

30.

Gaudino

Quaglio

Schiarelli

et al.

Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas. Neuroradiology 2012; 54: 989–995.

31.

Johnson

Guerin

Giannini

et al.

2016 Updates to the WHO Brain Tumor Classification System: What the radiologist needs to know. Radiographics 2017; 37: 2164–2180.

32.

Singh

Leeds

Ginsberg

. MR imaging of leptomeningeal metastases: Comparison of three sequences. AJNR Am J Neuroradiol 2002; 23: 817–821.

33.

Kremer

Abu Eid

Bierry

et al.

Accuracy of delayed post-contrast FLAIR MR imaging for the diagnosis of leptomeningeal infectious or tumoral diseases. J Neuroradiol 2006; 33: 285–291.

34.

Kim

Thompson

Governale

et al.

Recurrence after gross-total resection of low-grade pediatric brain tumors: The frequency and timing of postoperative imaging. J Neurosurg Pediatr 2014; 14: 356–364.

35.

Dorward

Luo

Perry

et al.

Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr 2010; 6: 346–352.

36.

Araujo

Trindade

Trompieri

et al.

Analysis of survival and prognostic factors of pediatric patients with brain tumor. J Pediatr (Rio J) 2011; 87: 425–432.